TipRanks
Advertisement
Advertisement
Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright
PremiumThe FlyPyxis Oncology price target raised to $8 from $7 at H.C. Wainwright
1M ago
Analyst Maintains Buy Rating on PYXS and Reiterates $6 Price Target on Promising MICVO Data
Premium
Ratings
Analyst Maintains Buy Rating on PYXS and Reiterates $6 Price Target on Promising MICVO Data
1M ago
Pyxis Oncology price target raised to $19 from $12 at Wells Fargo
Premium
The Fly
Pyxis Oncology price target raised to $19 from $12 at Wells Fargo
1M ago
Pyxis Oncology files to sell 39.2M shares of common stock for holders
PremiumThe FlyPyxis Oncology files to sell 39.2M shares of common stock for holders
2M ago
Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained
Premium
Ratings
Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained
2M ago
Pyxis Oncology reports Q2 EPS (40c), consensus (35c)
Premium
The Fly
Pyxis Oncology reports Q2 EPS (40c), consensus (35c)
2M ago
Pyxis Oncology announces up to $114M private placement
PremiumThe FlyPyxis Oncology announces up to $114M private placement
4M ago
Pyxis Oncology Stockholders Approve Directors and Auditor Slate
Premium
Company Announcements
Pyxis Oncology Stockholders Approve Directors and Auditor Slate
4M ago
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility
Premium
Company Announcements
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―